Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer
Status:
Completed
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
This phase 2 trial studies how well remetinostat works in treating patients with skin basal
cell cancer. Remetinostat may slow the growth of basal cell cancer cells.
Phase:
Phase 2
Details
Lead Sponsor:
Kavita Sarin
Collaborators:
American Skin Association Medivir National Institutes of Health (NIH)